{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"NuCana plc"},"Symbol":{"label":"Symbol","value":"NCNA"},"Address":{"label":"Address","value":"3 LOCHSIDE WAY, EDINBURGH, EH12 9DT, United Kingdom"},"Phone":{"label":"Phone","value":"+44 1313571111"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Geographically operates through the region of the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.nucana.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Elisabeth Oelmann","title":"Senior VP-Medical & Clinical Development"},{"name":"Hugh Stephen Griffith","title":"Chief Executive Officer & Executive Director"},{"name":"Jeffrey D. Bloss","title":"Chief Medical Officer"},{"name":"Michelle Myers","title":"Vice President-Medical & Scientific Affairs"},{"name":"Theresa Margaret Bruce","title":"Senior Vice President-Clinical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}